News

Epitope binning immunoassays using Fiber Optic Particle Plasmon Resonance (FOPPR™) technology could be deployed in the development of new potential drug candidates. Furthermore, it could accommodate up to four mAbs in one experiment run, enabling this characterization process to be more time- and material efficient for scientists.This webinar will discuss how FOPPR™ is used to characterize closely related “bins” of mAbs targeting the same epitope of the target protein and how the selection process is used in assay development. We also are pleased to invite AnTaimmuBioMed to share how they use FOPPR™ to develop COVID-19 related therapeutic antibodies and diagnostic tools.Speakers:Tony Chung (CEO of Instant NanoBiosensors)Dr. Ing-Chien Chen (Head of R&D Department of AnTaimmu BioMed)Topic: Epitope Binning: A Critical Step in Antibody DevelopmentDate: 10th Dec. 2021Time: 10:00am -10:45am CSTContact mail: bd@instantnano.comRegister: https://us02web.zoom.us/webinar/register/WN_rMiDBmmjTFOyg3qHRDKSSQ

Full article: https://www.digitimes.com/news/a20210720VL201.html

Instant NanoBiosensors was proudly featured in the Jul 2021 edition of Taiwan Tech Arena's (TTA) magazine! TTA in conjunction with the Ministry of Science and Technology support startup programs strive through the integration of various resources to boost innovative startups by linking them with international accelerators and expanding global reach to create more business opportunities. Read the full article here: Revolutionizing Biosensing Approaches with Light Sensing, Instant NanoBiosensors' FOPPR Technology Creates a Vision of Mutual Benefit

CDMO (contract development and manufacturing organization) is undoubtedly the new mainstream of international biomedicine and the development wave is on the rise. Instant Nanobiosensors Co. Ltd and Sartorius International Pharmaceutical Equipment Supplier were invited by Global Bio & Investment Monthly and Development Center for Biotechnology (DCB) in a webinar to share thoughts on how Taiwan's CDMO industry can improve and compete globally. The webinar mentioned opportunities for pharmaceutical industry and integration strategy alliance while iterating innovation, high-throughput, automation, and talent training as keys for breakthrough!「今日奈捷消息分享」CDMO，毫無疑問是國際生物醫藥新主流，發展浪潮正起，「奈捷生技」& CDMO大廠台康生技& Sartorius 國際製藥設備大廠，接受環球月刊和財團法人生物技術開發中心邀請，進行產業分享與整合策略聯盟的契機！突破臺灣CDMO發展創新、高通量、自動化、人力培養為關鍵https://reurl.cc/mLo6NG

We are proud to be a semi-finalist in Boston Scientific’s Connected Patient Health Challenge IV – Telehealth, for two categories: Improving the journey of stroke patients and point-of-care TBI brain biomarker analysis.Detection of stroke-specific biomarkers using our Light Sensing Biomarker POCT can guide stroke and TBI prognosis with the goal of shortening time-to-treatment, determination of stroke sub-types, and monitoring after treatment to prevent stroke recurrence. We hope through our system we can realize our dream of “immediate care” to make health care quicker, cheaper, and more comfortable without sacrificing quality.We are happy to work with you on any ultra-sensitive biomarker challenge you may have! https://connectedpatientchallenge.com/news/cpc-vi-semi-finalists-announced